Kymera Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for KT-333 to treat Relapsed/Refractory (R/R) Cutaneous T-Cell Lymphoma (CTCL) and Peripheral T-Cell Lymphoma (PTCL).
19 Sep 2023
23 Aug 2023
The European Commission (EC) has granted conditional marketing authorisation (CMA) to the Janssen Pharmaceutical Companies of Johnson & Johnson’s Talvey (talquetamab) for the treatment of relapsed and refractory multiple myeloma (RRMM) in adult patients who received a minimum of three prior lines of therapies.
21 Jul 2023
Emergent BioSolutions has announced receipt of the US Food and Drug Administration’s (FDA) approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), for post-exposure prophylaxis of disease after suspected or confirmed exposure to Bacillus anthracis in persons aged 18 through 65 years when administered along with recommended antibacterial drugs.
21 Jun 2023
Eli Lilly and Company has signed a definitive agreement to acquire a biopharmaceutical company DICE Therapeutics.
10 Feb 2023
Alvotech and global pharmaceutical company STADA Arzneimittel (STADA) announced that their Marketing Authorization Application for AVT04, the former’s proposed biosimilar to Stelara (ustekinumab), has been accepted by the European Medicines Agency (EMA).
02 Feb 2023
GSK has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its B-cell inhibiting monoclonal antibody Benlysta (belimumab) to potentially treat systemic sclerosis (SSc).
16 Jun 2022
Quoin Pharmaceuticals has signed a license and distribution agreement with Hong Kong WinHealth Pharma Group for its lead product candidate, QRX003 for Netherton Syndrome and a second pipeline product, QRX004 for Epidermolysis Bullosa.
16 Dec 2021
Boehringer Ingelheim has announced acceptance of a biologics license application (BLA) and granting of priority review by the US Food and Drug Administration (FDA) for spesolimab in treating generalized pustular psoriasis (GPP) flares.
07 Oct 2021
AstraZeneca subsidiary Alexion has concluded the takeover of all the outstanding shares of Caelum Biosciences in a deal worth up to $500m.
03 Sep 2021
Swedish Orphan Biovitrum (Sobi) has agreed a $8bn (SEK69.4bn) takeover offer from Advent International and Singapore’s wealth fund GIC.